SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CGEM reported Third Quarter 2026 results. The stock moved -4.3% on the print.
CGEMearnings

Earnings reactions, page 4

Cullinan Therapeutics, Inc. (CGEM) Q3 FY2026 earnings

November 10, 2026 · SharpeIQ Research Desk

Reported results

  • Research and development expenses were $40.2 million for the third quarter of 2026, compared to $42.0 million for the third quarter of 2025.
  • General and administrative expenses were $12.4 million for the third quarter of 2026, compared to $13.6 million for the third quarter of 2025.
  • Net loss was $49.4 million for the third quarter of 2026, compared to $50.6 million for the third quarter of 2025.
  • Basic and diluted net loss per share of common stock was $0.74 for the three months ended September 30, 2026, compared to $0.77 for the three months ended September 30, 2025.
  • Cash, cash equivalents, short- and long-term investments, and interest receivable were $313.8 million as of September 30, 2026.

Guidance

  • Cullinan expects its cash resources to provide runway into 2029 under its current operating plan.

Price and volatility reaction

The stock moved -4.3% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +18.6 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release11.732026-11-09
Close after release11.232026-11-10
Realised move-4.3%close to close
30d ATM IV change+18.6 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-10 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →